Access GPO in PFD strategic commercial pact with Medtronic

Medtronic plc (NYSE: MDT) has announced a strategic partnership with La Poste, a French postal and logistics company, to advance digital transformation in healthcare. This collaboration aims to leverage La Poste's infrastructure and Medtronic's medical technology expertise to improve healthcare delivery and patient outcomes. While specific financial terms of the agreement were not disclosed, the partnership aligns with Medtronic's broader strategy to integrate digital solutions into its diabetes and other therapeutic areas.

In related news, Medtronic Diabetes has expanded access to its MiniMed™ 780G automated insulin delivery system through new Medicare coverage and FDA clearances. The system, now compatible with Abbott's Instinct sensor, offers Medicare beneficiaries and individuals with type 1 or insulin-requiring type 2 diabetes enhanced flexibility in glucose management. The FDA also approved the use of ultra rapid-acting insulins (Fiasp and Lyumjev) with the MiniMed™ 780G system, enabling more personalized therapy options. These developments are expected to increase adoption of Medtronic's advanced diabetes technologies, particularly among Medicare-eligible patients.

The MiniMed™ 780G system automates insulin delivery based on real-time glucose readings, reducing the burden of manual dose adjustments. With Medicare access and broader sensor compatibility, Medtronic is positioning itself to capture a larger share of the diabetes technology market, which remains a key growth driver for the company. Analysts note that these milestones reflect Medtronic's commitment to expanding access to its innovations while addressing unmet needs in diabetes care.

La Poste and Medtronic announce a strategic partnership to accelerate digital transformation in healthcare.
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances.